All Brands Owned by Organon & Co.

Who owns Organon & Co.?
Organon & Co. is a publicly traded company listed on the New York Stock Exchange under ticker OGN. The company was created through a spin-off from Merck & Co. on June 3, 2021. Merck shareholders received one share of Organon for every ten Merck shares held. Shares are widely held by institutional investors, with no single shareholder exercising controlling influence. The company has a single class of common stock with no dual-class share structure. Interim CEO Joseph Morrissey has led the company since October 2025.

Why was Organon spun off from Merck?
Merck announced the spin-off in February 2020 to create two focused companies. Merck wanted to concentrate on its growth pillars in oncology, vaccines, and key products like Keytruda. The women's health, established brands, and biosimilars businesses, while generating $6.5 billion in 2020 revenue, were not central to Merck's long-term strategy. The spin-off was expected to deliver approximately $1.5 billion in incremental operating efficiencies for Merck over three years. In connection with the spin-off, Merck received a distribution of approximately $9 billion from Organon.

What is Organon's revenue?
Organon reported revenue of $6.2 billion in FY2025, down 3 percent from $6.4 billion in FY2024. Women's Health contributed $1.75 billion, Established Brands $3.69 billion, Biosimilars $691 million, and Other $82 million. Adjusted EBITDA was $1.91 billion, representing a 30.7 percent margin. Diluted EPS was $0.72, and adjusted diluted EPS was $3.66. For FY2026, the company guided to approximately $6.2 billion in revenue and approximately $1.9 billion in adjusted EBITDA.

What products does Organon own?
Organon owns over 70 medicines and products. Key women's health products include Nexplanon (contraceptive implant), NuvaRing (vaginal ring contraceptive), Cerazette (progestin-only pill), and Follistim AQ/Puregon (fertility treatment). Established brands include Propecia (finasteride for hair loss), Singulair (montelukast for asthma), Zetia, Arcoxia, and Renitec. Biosimilars include Renflexis, Ontruzant, and Hadlima. The dermatology portfolio includes VTAMA (tapinarof cream, acquired in October 2024), Diprosone, and Elocon.

Why did Organon's CEO resign?
CEO Kevin Ali resigned on October 26, 2025, after the company's audit committee completed an investigation into improper wholesaler sales practices for Nexplanon. The investigation found that certain US wholesalers were asked to purchase more Nexplanon than they needed at the end of multiple quarters in 2022, 2024, and 2025 to enable Organon to meet guidance and external revenue expectations. The board determined the practices were improper and that certain prior statements were inaccurate or incomplete. Ali agreed to forgo severance and equity-related retirement benefits. The company also terminated its head of US commercial and government affairs.

What is the JADA System divestiture?
In late 2025, Organon announced an agreement to divest its JADA System, a device for controlling postpartum uterine bleeding, to Laborie Medical Technologies for up to $465 million. The deal included $440 million upfront and up to $25 million in milestone payments based on 2026 revenue targets. The divestiture was completed on January 28, 2026, with approximately 100 employees transferring to Laborie. Organon acquired the JADA System through its 2021 acquisition of Alydia Health. The proceeds are being applied to debt reduction as part of the company's deleveraging efforts.

What is VTAMA?
VTAMA (tapinarof) cream is a non-steroidal topical treatment for plaque psoriasis in adults and atopic dermatitis in adults and children. Organon acquired VTAMA through its purchase of Dermavant Sciences Ltd. from Roivant Sciences, which closed on October 28, 2024. The total consideration was up to approximately $1.2 billion, including a $175 million upfront payment, a $75 million regulatory milestone, and up to $950 million in commercial milestones, plus tiered royalties. VTAMA is Organon's first major dermatology acquisition and represents the company's strategy of expanding into adjacent therapeutic areas.